← Back to Directory

Agenus Inc. (AGEN) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Agenus Inc. (AGEN).

Download StockRank on Google Play Download StockRank on the App Store

Equity Details

Price & Market Data

Price: $3.45

Daily Change: +$0.19 / 5.51%

Daily Range: $3.21 - $3.45

Market Cap: $142,892,624

Daily Volume: 799,543

Performance Metrics

1 Week: -17.51%

1 Month: -17.11%

3 Months: 12.05%

6 Months: -13.57%

1 Year: -1.71%

YTD: 9.55%

About Agenus Inc. (AGEN)

Essential overview of Agenus Inc. (AGEN). Price: 3.45, daily change: +$0.19 / 5.51%. Market cap: 142,892,624. YTD and 6-month performance insights.

Company Details

Employees: 81

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Selected stocks

AGNC Investment Corp. - Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock (AGNCM)

Pursuit Attractions and Hospitality, Inc. (PRSU)

ZenaTech, Inc. (ZENA)

Brixmor Property Group Inc. (BRX)

Shutterstock, Inc. (SSTK)